Search

Your search keyword '"Planchard, D"' showing total 349 results

Search Constraints

Start Over You searched for: Author "Planchard, D" Remove constraint Author: "Planchard, D" Journal annals of oncology Remove constraint Journal: annals of oncology
349 results on '"Planchard, D"'

Search Results

1. SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

6. SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

11. Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial

12. 259MO A predictive score of cancer immunotherapy responses based on ecological analysis of gut microbiota

13. 1259MO Encorafenib plus binimetinib in patients (pts) with previously untreated BRAF V600E-mutant advanced non-small cell lung cancer (NSCLC): An open-label, multicenter phase II trial (IFCT-1904 ENCO-BRAF).

14. Circulating L-arginine predicts the survival of cancer patients treated with immune checkpoint inhibitors

15. 145P Everolimus for the treatment of thymic epithelial tumors (TETs): A real-world experience

17. 1070P Previous viral infections assessed by pan-virus phage immunoprecipitation sequencing (PhIP-Seq) predict response to immune checkpoint blockers (ICBs) in non-small cell lung cancer (NSCLC)

18. 1090P HER2 copy number variation in non-small cell lung cancer (NSCLC)

19. 975P Trastuzumab deruxtecan in patients (pts) with HER2-overexpressing (HER2-OE) metastatic non-small cell lung cancer (NSCLC): Results from the DESTINY-Lung01 trial

20. 941P PET-derived parameters for response assessment in neoadjuvant atezolizumab: A secondary analysis of PRINCEPS phase II trial

21. 976P Phase II trial of trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutated (HER2m) metastatic non-small cell lung cancer (NSCLC): Registrational data from DESTINY-Lung01

22. LBA55 Trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutant metastatic non-small cell lung cancer (NSCLC): Interim results from the phase 2 DESTINY-Lung02 trial

23. 1661MO Genomic somatic copy number alterations drive adaptive tumor immune suppression and primary resistance to anti-PD1 + anti-angiogenics in pleural mesothelioma

30. 1260P Efficacy and safety of sunvozertinib in prior platinum treated NSCLC patients with EGFR exon 20 insertion mutations: Primary analysis from the multinational WU-KONG1B pivotal study

31. 1206MO ALINA: Exploratory biomarker analyses in patients (pts) with resected ALK+ non-small cell lung cancer (NSCLC) treated with adjuvant alectinib vs chemotherapy (chemo)

33. ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer

34. 34P RET-MAP: An international multi-center study on clinicopathologic features and treatment response in patients with NSCLC and RET fusions

35. 158P Real-world management of patients with EGFR exon 20-mutant NSCLC in the precision oncology era: First report from the European EXOTIC registry

36. Single-cell DNA-seq depicts clonal evolution of multiple driver alterations in osimertinib-resistant patients

37. 184P Association of tumor-associated neutrophils (TAN) with immunotherapy outcomes in patients in advanced non-small cell lung cancer

39. 25P Association between the lung immune prognostic index (LIPI) and durvalumab consolidation outcomes in patients with locally advanced non-small cell lung cancer (NSCLC)

40. Plasma proteomics identifies leukemia inhibitory factor (LIF) as a novel predictive biomarker of immune-checkpoint blockade resistance

42. Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial

44. 1267P Clinical utility of ctDNA for detection of EGFR, ALK, BRAFV600E alterations and resistance mutations in patients with NSCLC at failure to targeted therapy

45. 1735P Circulating T-cell immunosenescence in patients with thymic epithelial tumors (TETs)

46. 1200P BrigALK2 study: A multicentric real-world study evaluating brigatinib in ALK positive advanced pre-treated non-small cell lung cancers: Long-term follow-up with focus on lorlatinib efficacy after brigatinib

47. 1842P Molecular testing in older patients treated for an advanced or metastatic non-squamous non-small cell lung cancer

48. 1172MO Durvalumab consolidation in patients with stage III non-resecable NSCLC with driver genomic alterations

49. 1732MO Pembrolizumab and nintedanib for patients with advanced mesothelioma

50. 1361TiP Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-mutated (HER2m) metastatic non-small cell lung cancer (NSCLC): A phase (ph) II study (DESTINY-Lung02)

Catalog

Books, media, physical & digital resources